aTyr Pharma Advances Phase III Trial for Efzofitimod in Pulmonary Sarcoidosis Treatment

aTyr Pharma (ATYR) is making significant strides in the treatment of pulmonary sarcoidosis with its upcoming Phase III clinical trial for efzofitimod.

A New Clinical Trial Phase for efzofitimod

The recent meeting with the FDA emphasized the necessity of focusing on key metrics such as forced vital capacity (FVC) and the King's Sarcoidosis Questionnaire (KSQ) lung score. Although the previous Phase III EFZO-FIT study did not hit its primary target related to steroid reduction, it provided a valuable insight into quality-of-life improvements for patients, underscoring the drug's potential despite unmet endpoints.

Dr. Sanjay Shukla, President and CEO of aTyr Pharma, outlines that this new trial will specifically target individuals with restrictive lung disease, setting up a protocol for submission to the FDA shortly.

Trial Details and Objectives

The international, randomized, double-blind, placebo-controlled trial will enroll around 372 participants who are already on stable doses of corticosteroids. The primary measure of success will hinge on assessing FVC changes after 48 weeks, with the KSQ lung score serving as a secondary endpoint, potentially providing a dual measure of efzofitimod's effectiveness.

Strategic Changes in Dosing

Furthermore, the trial protocol suggests modifying the dosing schedule from monthly to tri-weekly, aimed at improving the drug's exposure while maintaining patient safety. This step could open up substantial avenues for aTyr in treating pulmonary sarcoidosis, enhancing its reach in the therapeutic landscape and strengthening its research-driven approach.